Chloroquine or hydroxychloroquine use during pregnancy not associated with adverse fetal outcomes
- PDF / 151,350 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 27 Downloads / 187 Views
1
Chloroquine or hydroxychloroquine use during pregnancy not associated with adverse fetal outcomes Use of chloroquine or hydroxychloroquine during pregnancy is not associated with an increased risk of major birth defects, preterm birth or small-for-gestational-age (SGA), according to a study from Denmark. The nationwide cohort study examined the fetal safety of 4-aminoquinoline use (i.e., chloroquine and hydroxychloroquine) among live-birth pregnancies for the period from January 1996 through December 2016. In particular, the risk of major birth defects associated with 4-aminoquinoline use, compared with propensity scorematched unexposed pregnancies, was investigated. The risks of preterm birth and SGA were also assessed. The data analysis showed that 1487 pregnancies were exposed to a 4-aminoquinoline during the study period (1184 with chloroquine exposure and 303 with hydroxychloroquine exposure). The analysis of data from 983 pregnancies exposed to 4-aminoquinolines in the first trimester showed no increased risk of major birth defects, with rates similar to those in matched unexposed pregnancies (3.5% vs 3.7%; prevalence odds ratio [OR] 0.94; 95% CI: 0.59, 1.52). There were also no significant associations between 4-aminoquinoline exposure and the risks of preterm birth (prevalence OR 0.97; 95% CI: 0.73, 1.28) or SGA (prevalence OR 1.18; 95% CI: 0.93, 1.50). Subgroup analyses of exposure to the individual 4-aminoquinolines during pregnancy showed no significant associations between chloroquine or hydroxychloroquine exposure and major birth defects, preterm birth or SGA, compared with matched unexposed pregnancies. "Although the possibility of adverse fetal effects associated with the use of 4-aminoquinolones cannot definitely be ruled out, the results provide reassurance regarding the use of these individual drugs during pregnancy when clinically indicated," conclude the researchers. Andersson NW, et al. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology : 24 Nov 2020. Available from: 803519787 URL: http://doi.org/10.1093/rheumatology/keaa592
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
